These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 16555862)

  • 1. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence.
    Daviglus ML; Lloyd-Jones DM; Pirzada A
    Am J Cardiovasc Drugs; 2006; 6(2):87-101. PubMed ID: 16555862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevention of cardiovascular disease: have we really made progress?
    Pearson TA
    Health Aff (Millwood); 2007; 26(1):49-60. PubMed ID: 17211013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacotherapy for primary prevention of cardiovascular disease.
    Xavier D; Devereaux PJ; Goyal A; Pais P; Yusuf S
    Indian Heart J; 2008; 60(2 Suppl B):B29-33. PubMed ID: 19359761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global burden of CVD: focus on secondary prevention of cardiovascular disease.
    Bansilal S; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S1-7. PubMed ID: 26747389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
    ; Yusuf S; Attaran A; Bosch J; Joseph P; Lonn E; McCready T; Mente A; Nieuwlaat R; Pais P; Rodgers A; Schwalm JD; Smith R; Teo K; Xavier D
    Eur Heart J; 2014 Feb; 35(6):353-64. PubMed ID: 24288261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of polypharmacy in cardiovascular medicine.
    Volpe M; Chin D; Paneni F
    Fundam Clin Pharmacol; 2010 Feb; 24(1):9-17. PubMed ID: 19817871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The global impact of noncommunicable diseases: estimates and projections.
    Manton KG
    World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases.
    Puska P; Vartiainen E; Tuomilehto J; Salomaa V; Nissinen A
    Bull World Health Organ; 1998; 76(4):419-25. PubMed ID: 9803593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Information and Risk Modification Trial (INFORM): design of a randomised controlled trial of communicating different types of information about coronary heart disease risk, alongside lifestyle advice, to achieve change in health-related behaviour.
    Silarova B; Lucas J; Butterworth AS; Di Angelantonio E; Girling C; Lawrence K; Mackintosh S; Moore C; Payne RA; Sharp SJ; Shefer G; Tolkien Z; Usher-Smith J; Walker M; Danesh J; Griffin S
    BMC Public Health; 2015 Sep; 15():868. PubMed ID: 26345710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease.
    Zomer E; Leach R; Trimmer C; Lobstein T; Morris S; James WP; Finer N
    Diabetes Obes Metab; 2017 Jan; 19(1):118-124. PubMed ID: 27649286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease.
    Selak V; Bullen C; Stepien S; Arroll B; Bots M; Bramley D; Cass A; Grobbee D; Hillis GS; Molanus B; Neal B; Patel A; Rafter N; Rodgers A; Thom S; Tonkin A; Usherwood T; Wadham A; Webster R
    Eur J Prev Cardiol; 2016 Sep; 23(13):1393-400. PubMed ID: 26945024
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.